Pembrolizumab with Bacillus Calmette-Guerin for treating high-risk non-muscle invasive bladder cancer


featured image

Pembrolizumab in combination with Bacillus Calmette-Guerin (BCG) is in development for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC) that is recurrent or persistent following BCG induction or naïve to BCG treatment.

Indications: Bladder cancer
Therapeutic Areas: Urological Cancer
Year: 2023

Pembrolizumab in combination with Bacillus Calmette-Guerin (BCG) is in development for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC) that is recurrent or persistent following BCG induction or naïve to BCG treatment. Bladder cancer is when cancerous cells develop in the lining of the bladder. NMIBC is the most common type of bladder cancer and is categorised by risk. High-risk NMIBC is when cancerous cells are likely to persist or return after treatment, this means people with this type might require additional treatment and monitoring. Current treatment for patients with high-risk NMIBC is surgery to remove the bladder and intravesical (through a catheter) BCG treatment. NMBIC recurrence rate is high when treated with BCG alone, and surgical removal of the bladder is an invasive procedure.